...mos and 3.7 mos in pts with SD. In pts treated with 400 mg imatinib there were no significant differences in PKs (t 22.0...
...mos (0.25+-9.6), median overall survival is 5.5+ mos (0.6-10.9+) (7 pts ongoing).,Combination of Cetuximab plus CAPOX ha...
...mos, when biopsies were repeated.,18 patients are evaluable at 3 mos, 10 at 12 mos. One patient was withdrawn for gr 2 a...
...mos (1-13.5 mos) with a 6-month progression-free probability rate of 43%. This difference in median TTP was highly signi...
...mos on adding 80 mg/M of Irinotecan to a 'failed' q2 wk Gemzar-Fluorouracil-Cisplatin regimen (The Oncologist 6:488 2001...
...mos; actuarial median OS (events:61%): 4 mos. Evaluation of clinical benefit is ongoing.,The weekly schedule of O-VNB is...
...MOs responded. Correlative testing of bx specimens was considered worthwhile by 96% of MOs. Clinical trials with mandato...
...mos of AST, for pts with clinically localized prostate cancer. Quality-of-life utility measures and cost data were obtai...
...mos, range 2 to 15. Mean TTPd 7.9 +/- 4.0 mos, range: 2 - 20. Twelve deaths has been registered (63.1%). Mean survival: ...
886 Background: IBC is the most aggressive form of breast cancer. The introduction of chemotherapy(CT) in multimodality ...
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话: 0531-88819269